|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rogers SN, Brown JS, Woolgar JA, Lowe D,
Magennis P, Shaw RJ, Sutton D, Errington D and Vaughan D: Survival
following primary surgery for oral cancer. Oral Oncol. 45:201–211.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bernier J, Cooper JS, Pajak TF, van
Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem
J, Ang KK and Lefèbvre JL: Defining risk levels in locally advanced
head and neck cancers: A comparative analysis of concurrent
postoperative radiation plus chemotherapy trials of the EORTC
(#22931) and RTOG (#9501). Head Neck. 27:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cooper JS, Zhang Q, Pajak TF, Forastiere
AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, et
al: Long-term follow-up of the RTOG 9501/intergroup phase III
trial: Postoperative concurrent radiation therapy and chemotherapy
in high-risk squamous cell carcinoma of the head and neck. Int J
Radiat Oncol Biol Phys. 84:1198–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lim JY, Lim YC, Kim SH, Kim JW, Jeong HM
and Choi EC: Predictive factors of isolated distant metastasis
after primary definitive surgery without systemic treatment for
head and neck squamous cell carcinoma. Oral Oncol. 46:504–508.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takahashi M, Aoki T, Nakamura N, Carreras
J, Kajiwara H, Kumaki N, Inomoto C, Ogura G, Kikuchi T, Kikuti YY,
et al: Clinicopathological analysis of 502 patients with oral
squamous cell carcinoma with special interest to distant
metastasis. Tokai J Exp Clin Med. 39:178–185. 2014.PubMed/NCBI
|
|
8
|
Bonner JA, Harari PM, Giralt J, Azamia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vermonken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hitt R, Irigoyen A, Cortes-Funes H, Grau
JJ, García-Sáenz JA and Cruz-hernandez JJ: Spanish Head and Neck
Cancer Cooperative Group (TTCC): Phase II study of the combination
of cetuximab and weekly paclitaxel in the first-line treatment of
patients with recurrent and/or metastatic squamous cell carcinoma
of head and neck. Ann Oncol. 23:1016–1022. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Péron J, Ceruse P, Lavergne E, Buiret G,
Pham BN, Chabaud S, Favier B, Girodet D, Zrounba P, Ramade A and
Fayette J: Paclitaxel and cetuximab combination efficiency after
the failure of a platinum-based chemotherapy in
recurrent/metastatic head and neck squamous cell carcinoma.
Anticancer Drug. 23:996–1001. 2012.
|
|
12
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, et al: New response evaluation
criteria in solid tumours: Revised RECIST guideline (version 1.1).
Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laskin JJ and Sandler AB: Epidermal growth
factor receptor: A promising target in solid tumours. Cancer Treat
Rev. 30:1–17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Agra IM, Carvalho AL, Pinto CA, Martins
EP, Filho JG, Soares FA and Kowalski LP: Biological markers and
prognosis in recurrent oral cancer after salvage surgery. Arch
Otolaryngol Head Neck Surg. 134:743–749. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R,
Hammond EH, Fu KK and Milas L: Impact of epidermal growth factor
receptor expression on survival and pattern of relapse in patients
with advanced head and neck carcinoma. Cancer Res. 62:7350–7356.
2002.PubMed/NCBI
|
|
17
|
Huang SM, Bock JM and Harari PM: Epidermal
growth factor receptor blockade with C225 modulates proliferation,
apoptosis and radiosensitivity in squamous cell carcinomas of the
head and neck. Cancer Res. 59:1935–1940. 1999.PubMed/NCBI
|
|
18
|
Zhang N, Erjala K, Kulmala J, Qiu X,
Sundvall M, Elenius K and Grénman R: Concurrent cetuximab,
cisplatin and radiation for squamous cell carcinoma of the head and
neck in vitro. Radiother Oncol. 92:388–392. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vermorken JB, Herbst RS, Leon X, Amellal N
and Baselga J: Overview of the efficacy of cetuximab in recurrent
and/or metastatic squamous cell carcinoma of the head and neck in
patients who previously failed platinum-based therapies. Cancer.
112:2710–2719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hasegawa T, Tanakura M, Takeda D,
Sakakibara A, Akashi M, Minamikawa T and Komori T: Risk factors
associated with distant metastasis in patients with oral squamous
cell carcinoma. Otolaryngol Head Neck Surg. 152:1053–1060. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sumioka S, Sawai NY, Kishino M, Ishihama
K, Minami M and Okura M: Risk factors for distant metastasis in
squamous cell carcinoma of the oral cavity. J Oral Maxillofac Surg.
71:1291–1297. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bulut OC, Lindel K, Hauswald H, Brandt R,
Klauschen F, Wolf J, Wolf T, Plinkert PK, Simon C, Weichert W and
Stenzinger A: Clinical and molecular characteristics of HNSCC
patients with brain metastases: A retrospective study. Eur Arch
Otorhinolaryngol. 271:1715–1722. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ruzevick J, Olivi A and Westra WH:
Metastatic squamous cell carcinoma to the brain: An unrecognized
pattern of distant spread in patients with HPV-related head and
neck cancer. J Neurooncol. 112:449–454. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan
PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar
AK, et al: Randomized phase III trial of concurrent accelerated
radiation plus cisplatin with or without cetuximab for stage III to
IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 32:2940–2950.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Touma W, Koro SS, Ley J, Wildes TM, Michel
L, Tao Y and Adkins D: Risk factors for and pre-medications to
prevent cetuximab-induced infusion reactions in patients with
squamous cell carcinoma of the head and neck. Oral Oncol.
50:895–900. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chung CH, Mirakhur B, Chan E, Le QT,
Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, et
al: Cetuximab-induced anaphylaxis and IgE specific for
galactose-alpha-1,3-galactose. N Engl J Med. 358:1109–1117. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Commins SP, James HR, Kelly LA, Pochan SL,
Workman LJ, Perzanowski MS, Kocan KM, Fahy JV, Nganga LW, Ronmark
E, et al: The relevance of tick bites to the production of IgE
antibodies to the mammalian oligosaccharide
galactose-α-1,3-galactose. J Allergy Clin Immunol.
127:1286–1293.e6. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Commins SP, Satinover SM, Hosen J, Mozena
J, Borish L, Lewis BD, Woodfolk JA and Platts-Mills TA: Delayed
anaphylaxis, angioedema, or urticaria after consumption of red meat
in patients with IgE antibodies specific for
galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 123:426–433.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
De Vos FY, Driessen CM, Jaspers HC, van
Herpen CM and Simons B: Cetuximab-induced pneumonitis in head and
neck cancer patient. Oral Oncol. 48:e17–e18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ishiguro M, Watanabe T, Yamaguchi K, Satoh
T, Ito H, Seriu T, Sakata Y and Sugihara K: A Japanese
post-marketing surveillance of cetuximab (Erbituxw®) in patients
with metastatic colorectal cancer. Jpn J Clin Oncol. 42:287–294.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baselga J, Trigo JM, Bourhis J, Tortochaux
J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A and
Eckardt A: Phase II multicenter study of the antiepidermal growth
factor receptor monoclonal antibody cetuximab in combination with
platinum-based chemotherapy in patients with platinum-refractory
metastatic and/or recurrent squamous cell carcinoma of the head and
neck. J Clin Oncol. 23:5568–5577. 2005. View Article : Google Scholar : PubMed/NCBI
|
